Graves病心力衰竭的发病率、危险因素、自然史与结局
该回顾性研究纳入1371例Graves病患者,随访期间74例(5.4%)发生新发心力衰竭,其中心室射血分数降低型31例(2.3%),射血分数保留型43例(3.1%)。心房颤动和高滴度促甲状腺激素受体抗体是射血分数降低型心衰的独立危险因素;慢性阻塞性肺疾病、年龄较大、显性甲状腺功能亢进、较高体质指数和高血压是射血分数保留型心衰的独立危险因素。两种类型心衰均增加心血管住院风险,但仅射血分数降低型心衰与全因死亡和室性心动过速/心室颤动风险增加相关。
要点
- Graves病患者新发心衰发生率5.4%,其中心室射血分数降低型2.3%,射血分数保留型3.1%。
- 心房颤动和促甲状腺激素受体抗体水平升高是射血分数降低型心衰的独立危险因素。
- 射血分数保留型心衰的危险因素包括慢性阻塞性肺疾病、年龄、显性甲亢、体质指数和高血压。
核心结论
- Graves病患者新发心衰发生率为5.4%,且与心血管住院风险增加相关。
- 仅射血分数降低型心衰与全因死亡和室性心动过速/心室颤动风险增加独立相关。
研究设计与样本
- 回顾性纳入2009至2019年Graves病患者1371例,采用比例风险回归分析危险因素与结局。
- 射血分数降低型心衰定义为左心室射血分数<50%且符合Framingham标准,射血分数保留型心衰根据HFA-PEFF标准定义,并排除缺血、瓣膜病或其他结构性心脏病所致心衰。
主要发现
- 1371例Graves病患者中74例(5.4%)发生心衰,其中心室射血分数降低型31例(2.3%),射血分数保留型43例(3.1%)。
临床怎么用
- 对Graves病患者应警惕新发心衰,尤其合并心房颤动、高滴度促甲状腺激素受体抗体、显性甲亢、高血压、较高体质指数或慢性阻塞性肺疾病者。
- 发生心衰的Graves病患者心血管住院风险显著增加,射血分数降低型心衰患者死亡和恶性室性心律失常风险更高,需加强监测与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Graves' disease (GD) can both aggravate pre-existing cardiac disease and cause de novo heart failure (HF), but large-scale studies are lacking. We aimed to investigate the incidence, risk factors and outcomes of incident GD-related HF. METHODS: Patients with GD (2009-2019) were retrospectively included. HF with reduced ejection fraction (HFrEF) was defined by left ventricular ejection fraction <50% and Framingham criteria, while HF with preserved ejection fraction (HFpEF) was defined according to the HFA-PEFF criteria. HF due to ischaemia, valve disorder or other structural heart disease was excluded. Proportional hazards regression was used to analyse risk factors and outcomes. RESULTS: Of 1371 patients with GD, HF occurred in 74 (5.4%) patients (31 (2.3%) HFrEF; 43 (3.1%) HFpEF). In HFrEF, atrial fibrillation (AF) (HR 10.5 (3.0-37.3), p<0.001) and thyrotropin receptor antibody (TRAb) level (HR 1.05 (1.01-1.09) per unit, p=0.007) were independent risk factors. In HFpEF, the independent risk factors were chronic obstructive pulmonary disease (HR 7.2 (3.5-14.6), p<0.001), older age (HR 1.5 (1.2-2.0) per 10 years, p=0.001), overt hyperthyroidism (HR 6.4 (1.5-27.1), p=0.01), higher body mass index (BMI) (HR 1.07 (1.03-1.10) per unit, p=0.001) and hypertension (HR 3.1 (1.3-7.2), p=0.008). The risk of cardiovascular hospitalisations was higher in both HFrEF (HR 10.3 (5.5-19.4), p<0.001) and HFpEF (HR 6.7 (3.7-12.2), p<0.001). However, only HFrEF was associated with an increased risk of all-cause mortality (HR 5.17 (1.3-19.9), p=0.02) and ventricular tachycardia/fibrillation (HR 64.3 (15.9-259.7), p<0.001). CONCLUSION: De novo HF occurs in 5.4% of patients with GD and is associated with increased risk of cardiovascular hospitalisations and mortality. Risk factors include AF, higher TRAb, higher BMI and overt hyperthyroidism.
引用
- Naser JA, Pislaru S, Stan MN, et al. Incidence, risk factors, natural history and outcomes of heart failure in patients with Graves' disease. Heart. 2022. PMID: 34489313. doi:10.1136/heartjnl-2021-319752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。